Oncolytics Biotech (ONCY) Other Operating Expenses (2009 - 2022)

Oncolytics Biotech (ONCY) has 14 years of Other Operating Expenses data on file, last reported at -$2.5 million in Q2 2022.

• On a quarterly basis, Other Operating Expenses fell 1071.95% year-over-year to -$2.5 million in Q2 2022; TTM through Mar 2023 was -$2.5 million, a 71.0% increase from a year earlier, with the FY2022 full-year figure at -$11.9 million, down 15.13% from the prior year.
• Other Operating Expenses for Q2 2022 stood at -$2.5 million, up from -$2.9 million in the prior quarter.
• Over the last five years, Other Operating Expenses for ONCY reached as high as $396261.2 in Q2 2020 and fell as low as -$3.1 million in Q3 2021.
• Historically, Other Operating Expenses has averaged -$1.1 million across 5 years, with a median of -$1.1 million in 2018.
• Across the five-year window, Other Operating Expenses soared 137.79% in 2019 and plunged 1071.95% in 2022, its largest moves.
• Year by year, Other Operating Expenses stood at -$461143.0 in 2018, then surged by 137.79% to $174277.0 in 2019, then plunged by 1065.38% to -$1.7 million in 2020, then tumbled by 73.49% to -$2.9 million in 2021, then climbed by 13.91% to -$2.5 million in 2022.
• Per Business Quant data, the three most recent Other Operating Expenses figures were -$2.5 million in Q2 2022, -$2.9 million in Q1 2022, and -$2.9 million in Q4 2021.